Trial Profile
An Open Label, Sequential, Dose Escalation, Repeat-dose Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRTX-100 in Adult Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Staphylococcal-protein-A (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Protalex
- 29 Sep 2014 New trial record